HUTCHMED Operating Margin from 2010 to 2024

HCM Stock  USD 17.68  0.28  1.56%   
HUTCHMED DRC Operating Profit Margin yearly trend continues to be very stable with very little volatility. Operating Profit Margin is likely to grow to -1.05 this year.
Check HUTCHMED DRC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HUTCHMED DRC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.9 M, Interest Expense of 879.4 K or Selling And Marketing Expenses of 31.2 M, as well as many indicators such as Price To Sales Ratio of 3.46, Dividend Yield of 0.0024 or PTB Ratio of 3.97. HUTCHMED financial statements analysis is a perfect complement when working with HUTCHMED DRC Valuation or Volatility modules.
  
Check out the analysis of HUTCHMED DRC Correlation against competitors.
To learn how to invest in HUTCHMED Stock, please use our How to Invest in HUTCHMED DRC guide.

Latest HUTCHMED DRC's Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of HUTCHMED DRC over the last few years. It is HUTCHMED DRC's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in HUTCHMED DRC's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (0.09) %10 Years Trend
Slightly volatile
   Operating Profit Margin   
       Timeline  

HUTCHMED Operating Margin Regression Statistics

Arithmetic Mean(0.42)
Coefficient Of Variation(113.45)
Mean Deviation0.42
Median(0.22)
Standard Deviation0.47
Sample Variance0.22
Range1.3614
R-Value(0.92)
Mean Square Error0.04
R-Squared0.85
Slope(0.1)
Total Sum of Squares3.12

HUTCHMED Operating Margin History

2024 -1.05
2023 -1.11
2022 -0.96
2021 -0.94
2020 -0.83
2019 -0.71
2018 -0.43

About HUTCHMED DRC Financial Statements

HUTCHMED DRC investors utilize fundamental indicators, such as Operating Margin, to predict how HUTCHMED Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
HUTCHMED Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchmed China operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 2110 people.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether HUTCHMED DRC is a strong investment it is important to analyze HUTCHMED DRC's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact HUTCHMED DRC's future performance. For an informed investment choice regarding HUTCHMED Stock, refer to the following important reports:
Check out the analysis of HUTCHMED DRC Correlation against competitors.
To learn how to invest in HUTCHMED Stock, please use our How to Invest in HUTCHMED DRC guide.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HUTCHMED DRC. If investors know HUTCHMED will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HUTCHMED DRC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.84)
Earnings Share
(0.25)
Revenue Per Share
3.575
Quarterly Revenue Growth
(0.43)
Return On Assets
(0.06)
The market value of HUTCHMED DRC is measured differently than its book value, which is the value of HUTCHMED that is recorded on the company's balance sheet. Investors also form their own opinion of HUTCHMED DRC's value that differs from its market value or its book value, called intrinsic value, which is HUTCHMED DRC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HUTCHMED DRC's market value can be influenced by many factors that don't directly affect HUTCHMED DRC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HUTCHMED DRC's value and its price as these two are different measures arrived at by different means. Investors typically determine if HUTCHMED DRC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HUTCHMED DRC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.